If phase 3 data replicates the Jastreboff phase 2 outcomes (24.2% weight loss sustained over 48 weeks) and achieves regulatory approval from the MHRA and EMA by 20272028, two pricing scenarios emerge: Scenario 1 (prescription approval): Retatrutide becomes a prescription-only medicine
So, it truly comes down to the clinical situation
David's DripGym consultation covered his physical therapy progress in detail, the specifics of his injury pattern, and an honest discussion of BPC-157's evidence base, including the fact that while animal model data were substantial, large-scale human randomized controlled trial data didn't yet exist
Incidentally, the healthy reference range is 191-663 pg/ml and correlates closely with oral cobalamin intake, which is why the vitamin B12 blood level alone is not an adequate parameter to diagnose a deficiency (Herrmann and Obeid, 2014)
Comment: A commenter stated that the requirement for consensus has not been met through broad acceptance of the measure by ASCs
